Exome Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Exome Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-88,024	Closed	-$2.13M	–	66
2025 Q3	$2.13M	Sell	88,024 -78,920	-47%	-$1.4M	1.29%	33
2025 Q2	$2.19M	Buy	166,944 +24,200	+17%	+$307K	1.63%	25
2025 Q1	$2.05M	Buy	142,744 +5,028	+4%	+$82.3K	1.82%	25
2024 Q4	$2.31M	Sell	137,716 -436	-0.3%	-$7.22K	1.73%	23
2024 Q3	$2.21M	Sell	138,152 -136,748	-50%	-$1.68M	1.49%	31
2024 Q2	$2.48M	Hold	274,900	–	–	2.21%	21
2024 Q1	$3.11M	Buy	+274,900	New	+$2.6M	2.66%	10

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Exome Asset Management's CNTA Position: Q4 2025 in Review

Exome Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 88,024 shares — an estimated $2.13M sold.

Exome Asset Management first reported a position in CNTA in Q1 2024 and held it in 7 quarters. The position peaked at $3.11M in Q1 2024. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

Exome Asset Management reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Exome Asset Management sold 88,024 Centessa Pharmaceuticals shares in Q4 2025, an estimated $2.13M.
Exome Asset Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Exome Asset Management's Centessa Pharmaceuticals position peaked at $3.11M in Q1 2024.
146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.